Aladdin Healthcare Technologies SE has just founded Aladdin Healthcare Technologies China Ltd. together with an extensive network of scientists, pharmacologists and healthcare practitioners including IIAT. The goal of the joint venture (JV), in which Aladdin Healthcare holds a 51% stake, is the further global development and marketing of an AI-based drug discovery tool. The tool supports basic clinical research for the development of new drugs for age-related diseases such as Alzheimer's, cardiovascular diseases, pulmonary diseases, diabetes and osteoporosis.